Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Arcoxia MEDAL Results Will Likely Not Meet FDA Gold Standard

Executive Summary

Despite the release of positive results from a long-term cardiovascular safety trial of its Vioxx follow-on Arcoxia, Merck will likely need to conduct additional studies before receiving FDA approval of the COX-2 inhibitor
Advertisement

Related Content

Negative Arcoxia Review May Reflect Increasingly High Hurdle For Me-Toos
Negative Arcoxia Review May Reflect Increasingly High Hurdle For Me-Toos
Arcoxia Needs Further Study In 1,000s Of Patients, Or Discontinuation – Cmte
2007 NME Prospects Plentiful For Wyeth, Novartis – Other Firms Fall Short
More COX-2 meta-analysis
Celebrex Heart Risk To Be Assessed By Cleveland Clinic In Pfizer-Funded Study
Pfizer Celebrex Revised Labeling Adds Class Cardio Risk, Moves Safety Data
Merck May Need New Arcoxia Trial Design Prior To FDA Approval
FDA Discloses Safety Reviews Of COX-2s Arcoxia, Prexige and Parecoxib
FDA Discloses Safety Reviews Of COX-2s Arcoxia, Prexige and Parecoxib
Advertisement
UsernamePublicRestriction

Register

PS047517

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel